A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 31/7088 (2006.01) A61K 39/21 (2006.01) A61K 39/39 (2006.01) A61K 47/48 (2006.01) A61K 48/00 (2006.01) C07H 21/02 (2006.01) C07H 21/04 (2006.01)
Patent
CA 2411167
Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine formulations are disclosed which are useful in prophylactic or therapeutic vaccine and/or gene therapy-based applications. These adjuvants comprise a block copolymer and a cationic surfactant component. The inclusion of a cationic surfactant results in an increased percentage of polynucleotide that is physically associated with the adjuvant in vitro, resulting in enhanced in vivo immune responses to polynucleotide vaccines.
La présente invention concerne des adjuvants améliorés pour des vaccins polynucléotidiques et des formulations de vaccins polynucléotidiques de ce type qui sont utiles dans des applications de vaccins prophylactique ou thérapeutique et/ou dans des applications fondées sur la thérapie génique. Ces adjuvants comprennent un copolymère séquencé et un constituant tensioactif cationique. Le fait d'introduire un tensioactif cationique a pour effet de produire un pourcentage accru du polynucléotide qui est physiquement associé à l'adjuvant in vitro et génère ainsi des réponses immunitaires in vivo accrues aux vaccins polynucléotidiques.
Gowling Lafleur Henderson Llp
Merck & Co. Inc.
LandOfFree
Polynucleotide vaccine adjuvants and formulations containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotide vaccine adjuvants and formulations containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotide vaccine adjuvants and formulations containing... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1388229